Compare Monolithic Power Systems Inc (MPWR) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Monolithic Power Systems Inc trades at $1,227 (market cap $64.85B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Monolithic Power Systems Inc is far larger — about 66.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Monolithic Power Systems Inc pays a 0.61% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| MPWR | MRVI | |
|---|---|---|
Market Cap | $64.85B | $972.90M |
Volume | 692,538 | 4,325,710 |
Sector | Technology | Health |
52-Week High | $1.69K | $9.00 |
52-Week Low | $856.96 | $2.83 |
Typical Hold Time | 25 Days | 0 Days |
Enterprise Value | $63.45B | $1.08B |
Dividend Yield | 0.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,319.55 with minimal daily movement (+0.02%) amid a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats, 24.5% net margins, and robust revenue growth from $2.8B to $3.3B year-over-year. Recent news highlights CEO share sales and a manufacturing partnership with GlobalFoundries to support AI and data center demand. Valuation remains elevated with P/E at 80.5 and P/S at 19.7, reflecting high growth expectations.
The outlook remains positive given analyst consensus (88% buy ratings) and a $1,830 price target, but risks include premium valuation compression, insider selling, and dependence on AI infrastructure growth. Cash flow strength supports dividend payments, though technical weakness near key support at $1,300 requires monitoring for sustained bullish momentum.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
